FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.
What happened
FDA reviewed https://pharmazee.co in December 2025 and found it offers compounded (custom-mixed) semaglutide and tirzepatide drug products. FDA says pictured labels show PharmaZee, suggesting PharmaZee is the maker of the custom-mixed drugs when it is not. The website also used claims such as “clinically proven medications,” “proven prescription medications,” and “Same active ingredient as Ozempic® and Wegovy®,” which FDA says imply FDA approval or evaluation that the products have not received.
What FDA found
FDA says pictured labels suggest PharmaZee is the maker of the custom-mixed drugs when it is not, making them misbranded (mislabeled or falsely presented).
FDCA § 502(a) [21 U.S.C. § 352(a)]; FDCA § 502(bb) [21 U.S.C. § 352(bb)]FDA says the claims “clinically proven medications” and “proven prescription medications” falsely imply the compounded drugs are proven or FDA-evaluated.
FDCA § 502(a) [21 U.S.C. § 352(a)]; FDCA § 502(bb) [21 U.S.C. § 352(bb)]FDA says the claim “Same active ingredient as Ozempic® and Wegovy®” falsely implies FDA approval, safety, or effectiveness.
FDCA § 502(a) [21 U.S.C. § 352(a)]; FDCA § 502(bb) [21 U.S.C. § 352(bb)]FDA says the misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
Within 15 working days, send a written response to OCQC/CDER describing steps taken to correct the violations and prevent recurrence, including identifying the entities that produce the compounded products, providing sample labeling, and addressing or removing questionable website claims.
Who should pay attention
- telehealth and online pharmacy platforms selling compounded GLP-1 drugs
- compounders whose products are marketed on third-party websites
- marketing and regulatory teams for compounded drug websites
This is a summary. Read the original letter on fda.gov.